Evidence map›Paper›PMID 39323743›Full record

ArticleRegenerative biomaterials2024

Combined therapeutic strategy based on blocking the deleterious effects of AGEs for accelerating diabetic wound healing.

Yang Yang, Siwen Huang, Qing Ma, Ning Li, Runchu Li, Yongjun Wang, Hongzhuo Liu

Abstract read
In one paragraph

Article in Regenerative biomaterials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yang YangDepartment of Pharmaceutics, College of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
Siwen HuangDepartment of Pharmaceutics, Wuya Collage of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Qing MaDepartment of Pharmaceutics, Wuya Collage of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Ning LiDepartment of Pharmaceutics, Wuya Collage of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Runchu LiBeijing No. 4 High School International Campus, Beijing 100031, China.
Yongjun WangDepartment of Pharmaceutics, Wuya Collage of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Hongzhuo LiuDepartment of Pharmaceutics, Wuya Collage of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic foot ulcer is a serious complication of diabetes. Excessive accumulation of advanced glycation end products (AGEs) is one of the critical pathogenic factors in postponing diabetic wound healing. The main pathogenic mechanisms of AGEs include inducing cellular dysfunction, prolonging inflammatory response, increasing oxidative stress and reducing endogenous nitric oxide (NO) production. Combination therapy of blocking the deleterious effects of AGEs and supplementing exogenous NO is hypothesized to promote diabetic wound healing. Here, we presented nanoparticles/hydrogel composite dressings to co-delivery rosiglitazone and S-nitroso glutathione into the wound bed. The designed co-delivery system augmented the survival of fibroblasts, reduced oxidative stress levels, reversed the change of mitochondrial membrane potential and decreased the proinflammatory cytokine expression. Local sustained release of therapeutic agents significantly improved the wound healing of diabetic rats including increasing the wound closure rate, alleviating inflammation, promoting collagen fiber production and angiogenesis. Our finding indicated this local deliver strategy aimed at inhibiting the toxic effects of AGEs has great clinical potential for diabetic wound treatment.

Indexed as

advanced glycation end productschronic skin woundscombined therapeutic strategylocalized co-deliveryNPs/hydrogel composite dressings

Identifiers

PMID39323743
PMCPMC11424028

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.